Sec61 inhibitor KZR-834, an anti-cancer agent, exhibits immunomodulatory activity and combines with PD-1 blockade to further enhance immune responses
American Association for Cancer Research Annual Meeting 2022
KZR-616, A Selective Immunoproteasome Inhibitor for the Treatment of Systemic Lupus Erythematosus: Results From the Completed Dose Escalation Phase 1b Portion of the MISSION Study
European Congress of Rheumatology (EULAR) 2021
Quantitative Proteomic Profiling of Novel Anti-cancer Small Molecule Inhibitors of Sec61: Mechanistic Investigation and Biomarker Discovery
American Association for Cancer Research Annual Meeting 2021
Prioritizing tumor types for clinical study of novel Sec61 inhibitors by searching for expression profiles of sensitive cell lines in tumor sample databases
American Association for Cancer Research Annual Meeting 2021
Small Molecule Inhibitors of Sec61 Cotranslational Translocation Regulate Phagocytosis Checkpoint Molecule CD47
SITC 35th Anniversary Meeting
Treatment of SLE With or Without Nephritis With the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
American College of Rheumatology (ACR) Convergence 2020
KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model
American College of Rheumatology (ACR) Convergence 2020
Blockade of Cytokine Production and Attenuation of Experimental Arthritis Progression by Novel Small Molecule Inhibitors of Sec61-Dependent Protein Secretion
8th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2020)
